Surveillance decision

Surveillance decision

We will not update the NICE guideline on psychosis and schizophrenia in children and young people. We will monitor the evidence base for new evidence in the following areas and assess its impact as it publishes:

  • The effectiveness of antipsychotics for preventing transition to full psychosis in children and young people with psychotic symptoms or mental state changes insufficient for a diagnosis of psychosis or schizophrenia.

  • Lurasidone for treating first episode and subsequent acute episodes of schizophrenia.

  • The benefit of adding cognitive behavioural therapy (CBT) to standard care including antipsychotics.

  • Weight management interventions for children, young people and adults receiving antipsychotics for psychosis and schizophrenia and bipolar disorder; and for children and young people receiving them for antisocial behaviour and conduct disorders.

Reasons for the decision

The evidence we identified is either equivocal, supports recommendations, or is not considered enough on its own to change them. We identified new evidence that indicated practice in some areas was developing rapidly and we propose actively monitoring those areas for new evidence that may impact recommendations.

For further details and a summary of all evidence identified in surveillance, see appendix A.

This page was last updated: